abbott.mediaroom

Abbott receives FDA approval for new CardioMEMS HF System capabilities that help patients engage in the care of their heart condition

For the first time, U.S. CardioMEMS patients will be able to view pulmonary artery pressure (PAP) readings and receive personalized medication updates through the CardioGuide HF App Rising PAP ...
abbott.mediaroom

Abbott introduces Ensure® Max Protein 3-in-1 Muscle Support, bringing the benefits of a supplement stack into one scoop

New powder combines 30 grams of high‑quality protein to help build muscle tissue,† 5 grams of creatine monohydrate to support ...
abbott.mediaroom

Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes

Libre Duo 10 Day is a first-of-its-kind, two-in-one biowearable that monitors glucose and helps detect rising ketone levels that can lead to diabetic ketoacidosis (DKA), a serious health condition for ...
abbott.mediaroom

Abbott Launches New PROTALITY™ Brand to Support Adults on Their Weight Loss Journey

The PROTALITY™ brand provides nutritional support for adults pursuing weight loss in the form of a high-protein nutrition shake featuring a blend of fast- and slow-digesting protein designed to feed ...
abbott.mediaroom

Abbott Reports Third-Quarter 2025 Results and Reaffirms Full-Year Guidance

The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information." Restructuring and cost reduction initiative ...
abbott.mediaroom

Abbott Reports Second-Quarter 2025 Results

The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information." Reflects the net tax benefit associated with the ...
abbott.mediaroom

Abbott Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Financial Outlook

The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information." Restructuring and cost reduction initiative ...
abbott.mediaroom

Abbott Reports First-Quarter 2024 Results and Raises Midpoint of Full-Year Guidance Ranges

The table above provides additional details regarding the specified items described on tables titled "Non-GAAP Reconciliation of Financial Information." Restructuring and cost reduction initiative ...
abbott.mediaroom

Abbott Reports Third-Quarter 2023 Results and Raises Midpoint of Full-Year EPS Guidance Range

The table above provides additional details regarding the specified items described on tables titled "Non-GAAP Reconciliation of Financial Information". a) Acquisition-related expenses include ...
abbott.mediaroom

Abbott Reports Fourth-Quarter and Full-Year 2023 Results; Issues 2024 Financial Outlook

The table above provides additional details regarding the specified items described on tables titled "Non-GAAP Reconciliation of Financial Information." a) Acquisition-related expenses include ...
abbott.mediaroom

Abbott's FreeStyle® Libre 2 iCGM Cleared in U.S. for Adults and Children with Diabetes, Achieving Highest Level of Accuracy and Performance Standards

- FreeStyle Libre 2 is the only integrated continuous glucose monitoring (iCGM) system available that continuously transmits glucose data every minute with customizable, optional real-time alarms to ...
abbott.mediaroom

Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance

Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $101 million of ...